Inclusion Criteria:

• Age greater than 18 and able to provide consent.

• Diagnosis of fibrotic interstitial lung disease defined by the presence of greater than 10% fibrotic changes on CT imaging within 6 months of study enrollment.

• Cough lasting greater than 3 months at the time of study enrollment.

• Any disease severity based on pulmonary function testing.

• Any treatment approach includes steroids, immune modulators, and antifibrotic agents.

• Patient may be enrolled in other research studies

Exclusion Criteria:

• Patients without research authorization,

• Patients <18 years of age

• Patients with acute respiratory tract infection

• Patients with asthma or COPD exacerbation at the visit

• Pregnant or lactating women

• Active smokers using cigarettes, vaping, electronic cigarettes, cannabis within the last 2 weeks

• Patients on use of angiotensin converting enzyme inhibitors

• Patients with bronchiectasis

• Patients with lung cancer

• History of cognitive decline

• History of aspiration/ aspiration pneumonia

• History of dysphagia

• Acute congestive heart failure exacerbation

• History of mitral stenosis

• Patients in their end of life care

• Less than 10% fibrosis on CT imaging

• Cough lasting less than 3 months at the time of study enrollment.

• Cognitive or memory impairment with inability to complete questionnaires.

• Patients unwilling to wear actigraph and or cough monitor for 7 days.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

 Eligibility last updated 03/03/2026. Questions regarding updates should be directed to the study team contact.